There are three automated insulin delivery devices on the U.S. market, two of which are currently approved by the U.S. Food and Drug Administration. These systems have already made a significant impact for the people who use them in improving diabetes outcomes, including glycemic control and hypoglycemia prevention. This article aims to help primary care and endocrinology providers better understand the components, differences, limitations, and potential fit of these systems into clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755048 | PMC |
| http://dx.doi.org/10.2337/cd20-0050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Automated insulin delivery in pregnant women with type 1 diabetes: a systematic review and meta-analysis.
Acta Diabetol
January 2025
Department of Emergency, Tianjin Fifth Central Hospital (Peking University Binhai Hospital), Tianjin, 300450, China.
Aim: The outcomes of automated insulin delivery (AID) systems in pregnant women with type 1 diabetes (T1D) have not been systematically evaluated. This study aims to evaluate the efficacy and safety of AID in pregnancy.
Material And Methods: Literature searches were conducted until July 5, 2024, on Embase, PubMed, Cochrane Library, and ClinicalTrials.
Changes in 90-Day Time in Range Among Youth with Type 1 Diabetes Initiating Different Automated Insulin Delivery Systems.
J Clin Endocrinol Metab
January 2025
Children's Hospital of Philadelphia, Philadelphia, PA, 19104.
Objective: Glycemic outcomes in youth with type 1 diabetes (T1D) in the United States using the two most common automated insulin delivery (AID) systems, Insulet Omnipod 5 (OP5) and Tandem Control IQ (CIQ), have not been compared. We performed the first head-to-head analysis of changes in glycemic metrics among youth initiating AID.
Methods: This single center, retrospective study included youth <21 years with T1D, who started OP5 or CIQ between 1/2020 and 12/2023, and had ≥70% CGM active time.
Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
Nat Med
January 2025
Division of Endocrinology & Metabolism, McGill University Health Centre, Montréal, Quebec, Canada.
Article Synopsis
- Ongoing efforts aim to enhance glycemic control in type 1 diabetes, focusing on semaglutide as a potential adjunct to automated insulin delivery therapy in adults.
- A randomized, double-blind crossover trial was conducted with 28 participants, where semaglutide or placebo was used, showing a significant increase in the time spent within the target glucose range by an average of 4.8 percentage points.
- No severe complications like diabetic ketoacidosis or hypoglycemia were reported, indicating that semaglutide is a safe and effective option for improving blood sugar levels in this context.
Automated insulin delivery in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis.
Acta Diabetol
January 2025
1st Paediatric Department, School of Medicine, Faculty of Health Sciences, Ippokratio General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aims: To assess the efficacy and safety of automated insulin delivery (AID) systems compared to standard care in managing glycaemic control during pregnancy in women with Type 1 Diabetes Mellitus (T1DM).
Methods: We searched MEDLINE, Cochrane Library, registries and conference abstracts up to June 2024 for randomized controlled trials (RCTs) and observational studies comparing AID to standard care in pregnant women with T1DM. We conducted random effects meta-analyses for % of 24-h time in range of 63-140 mg/dL (TIR), time in hyperglycaemia (> 140 mg/dl and > 180 mg/dL), hypoglycaemia (< 63 mg/dl and < 54 mg/dL), total insulin dose (units/kg/day), glycemic variability (%), changes in HbA1c (%), maternal and fetal outcomes.
Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.
J Diabetes Investig
January 2025
Diabetes Center, Ebina General Hospital, Ebina City, Kanagawa, Japan.
Low-density lipoprotein cholesterol (LDL-C) is known to be a causal substance of atherosclerosis, but its usefulness as a predictive biomarker for atherosclerotic cardiovascular disease (ASCVD) is limited. In patients with type 2 diabetes (T2D), LDL-C concentrations do not markedly increase, while triglycerides (TG) concentrations are usually elevated. Although TG is associated with ASCVD risk, they do not play a direct role in the formation of atheromatous plaques.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!